GA, all the info we need to know regarding Provista' intentions to reverse merge into Radient's shell is a matter of public record. The doubt our friendly skeptics have is the time element- the evidence is several years old.
You and I say The Plan is still intact, others disagree. Based on Provista's Current Need for DR-70 in both their impending Breast and Lung Cancer tests, I say the merger is ON.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.